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Evaluation of the potential of Raman Microspectroscopy for prediction 
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Abstract 
 
The study of the interaction of anticancer drugs with mammalian cells in vitro is important to elucidate the mechanisms of action of the 
drug on its biological targets. In this context, Raman spectroscopy is a potential candidate for high throughput, noninvasive analysis. To 
explore this potential, the interaction of cis-Diamminedichloroplatinum (II) (Cisplatin) with a human lung adenocarcinoma cell line 20 
(A549) was investigated using Raman microspectroscopy. The results were correlated with parallel measurements from the MTT 
cytotoxicity assay, which yielded an IC50 value of 1.2±0.2 μM. To further confirm the spectral results, Raman spectra were also acquired 
from DNA extracted from A549 cells exposed to cisplatin and from unexposed controls. Partial least squares (PLS) multivariate 
regression and PLS Jack-knifing were employed to highlight spectral regions which varied in a statistically significant manner with 
exposure to cisplatin and with the resultant changes in cellular physiology measured by the MTT assay. The results demonstrate the 25 
potential of the cellular Raman spectrum to non-invasively elucidate spectral changes that have their origin either in the biochemical 
interaction of external agents with the cell or its physiological response, allowing the prediction of the cellular response and the 




For the design of new anticancer drugs, an in-depth 
understanding of the mechanisms underlying their 
biological effects is required. It is therefore of interest to 
understand details of the molecular and biochemical 35 
mechanisms associated with the biological activity of 
existing commercial anti-cancer agents. The potential of 
confocal Raman microspectroscopy (CRM) for the 
analysis of biological tissue1 and the effect of external 
agents on the cell2-6 has been demonstrated. CRM is non-40 
invasive, cost effective, rapid and requires no sample 
labelling prior to analysis7. The technique, with its 
counterpart Fourier transform infrared microspectroscopy, 
has great potential to explore sub-cellular biochemical 
structure as exemplified by its use in studies investigating 45 
the action of various agents on biological macromolecules 
as well as their interaction with cancer cells7-13.  
 
Validation of CRM in the quantitative measurement of the 
biochemical and physiological effects of known 50 
chemotherapeutic agents is required before it may be used 
for studies of novel chemical treatments. Cisplatin (cis-
Diamminedichloroplatinum (II)) is a well established 
chemotherapeutic agent with a known mode of action. In 




intra-strand crosslinks which lead to cell cycle arrest and 
apoptosis14. The formation of inter-strand and intra-strand 60 
crosslinks between cisplatin and DNA leads to 
conformational changes of the DNA. To understand the 
changes caused in DNA conformation due to the adducts 
formed by cisplatin, the formation of 1,2-GG or 1,3-GTG 
intra-strand cross-links and their characterization by 65 
Raman spectroscopy has been carried out15 and it was 
found that 1,3 GTG cross linkages induce more distortion 
in the B-form DNA as compared to the 1,2-GG complex. 
 
The aim of the current study is to evaluate the quantitative 70 
predictive capabilities of CRM in the elucidation of the 
mode of action of chemotherapeutic agents, using cisplatin 
and A549 adenocarcinoma cells as a model compound and 
test system respectively. Spectra of the cellular nuclei were 
taken after a 96 hour exposure period to the agent, and 75 
multivariate models of the variation in spectral content 
with levels of exposure and with degrees of 
cytotoxicological response were constructed. A feature 
selection technique was then used to identify regions of the 
spectrum that were associated with the biochemical effect 80 
of exposure to the agent, and with the subsequent 
cytotoxicological response of the cells. It is demonstrated 
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that the CRM data, in conjunction with multivariate 
modeling, is capable of identifying spectral signatures of 
both the biochemical action and physiological response to 
exposure to the chemotherapeutic agent, and that the 
measurement may be used in predicting both responses in 5 
cancer cells. 
 
Materials and methods 
 
Cell culture 10 
A549 human lung adenocarcinoma cells were obtained 
from ATCC (CCL-185). The cells were cultured in DMEM 
F-12 (Sigma Aldrich, Ireland) medium supplemented with 
10% FBS, 1μg/ml hydrocortisone (Sigma), 2mM L-
glutamine (Gibco) and 1% penicillin- streptomycin 15 
(Gibco). Cells were incubated at 37°C in 5% CO2 and 
routinely subcultured with 1:1 ratio of 0.25% trypsin and 
0.1% EDTA when they reached 70-80% confluency.  
 
Cytotoxicity assay 20 
Cisplatin, obtained from Sigma Aldrich, Ireland, was 
dissolved in 1% NaCl (Sigma Aldrich, Ireland) solution 
(pH 7) to prepare the stock solution. Working solutions of 
the drug were prepared in cell culture media. MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 25 
was obtained from Sigma Aldrich, Ireland. The MTT assay 
was performed in triplicate according to a method reported 
previously16, 17 with a slight modification. MTT is a yellow 
coloured molecule that is converted to purple formazan by 
mitochondrial reductases in living cells, and thus 30 
measurements of its absorbance are indicative of the level 
of cellular metabolic activity and the consequent levels of 
DNA repair activity and cell death after exposure to 
Cisplatin. A 96-hour exposure period to Cisplatin was 
chosen along with a wide range of exposure concentrations 35 
as this provided a wide range of measurements of degrees 
of cytotoxicity with which to challenge the predictive 
ability of the Raman spectral measurement. 
 
The MTT measurement protocol was as follows. Cells 40 
were cultured in 96-well plates (Nunc, Denmark) at a 
density of 2  103 cells per well in DMEM-F12 medium 
with all the supplements as listed above. After 24 hrs of 
initial cell attachment, the plates were washed with 100 
μl/well phosphate buffered saline (PBS) and were treated 45 
with varying concentrations of cisplatin in the range from 
0.05 μM- 50μM (including a separate unexposed control 
sample). Following a 96-hour exposure period, the cells 
were rinsed with PBS and 100 μl of fresh medium (without 
supplements) were added to each well. A volume of 10l 50 
of MTT (5mg/ml) prepared in PBS was then added to each 
well and the plates were incubated for 3 hrs16 at 37 °C in a 
5% CO2 humidified incubator. After this incubation period, 
the medium was discarded, the cells were washed with 100 
μl of PBS and 100 μl of DMSO were added to each well to 55 
extract the dye. The plates were then shaken 240 times per 
minute for 10 min and the absorbance was measured at 570 
nm using a micro plate reader (Tecan Genios, Grodig, 
Austria). Six replicate wells were used for each exposure.  
 60 
Sample preparation for Confocal Raman Microspectroscopy 
For CRM, cell samples were cultured on quartz substrates 
according to a protocol outlined elsewhere6. Briefly, quartz 
coverslips were coated with a 2% w/v gelatin-water 
solution and maintained at 4 °C for 6 hrs to allow 65 
polymerization of the gelatin to the substrate. 
Subsequently, 2.5  103 A549 cells were attached to the 
substrates for a 48 hour period, and were exposed to the 
cisplatin concentrations employed for the cytotoxicity 
assay for a 96-hour period (together with a non-exposed 70 
control sample). After the exposure period, the cells were 
fixed in 4% formalin for 10 minutes and were stored in 0.9 
% physiological saline solution at 4 °C until the Raman 




The cellular DNA was extracted from both a control 
sample of A549 cells together with a sample of A549 cells 
exposed to 3 μM cisplatin for 96 hours. As determined 80 
using the cytotoxicity assay, at this concentration, the 
viability has reduced to approximately 30% and thus it 
represents the 1/e point of the response. Briefly, cells were 
trypsinised and centrifuged to form a pellet of cells, and 1 
ml TRIzol reagent (Invitrogen) per 5 - 10  106 cells was 85 
added. The samples were then homogenized and incubated 
at room temperature for 5 min to induce cell lysis. For each 
ml of TRIzol reagent, 200 μl of chloroform was added and 
samples were centrifuged at 12,000 × g for 5 min at 4 °C. 
Following centrifugation, the mixture separated out into a 90 
lower red organic phase, a thin interphase and a colourless 
upper aqueous phase. The DNA was precipitated from the 
interphase and organic phase with 300 μl of 100% ethanol 
per ml of TRIzol reagent. Once precipitated, the DNA was 
washed twice in a solution of 0.1M trisodium citrate in 95 
10% ethanol. The DNA was then dissolved in dH2O as 
water has a significantly weaker Raman signal than 
common organic solvents. Samples were mixed by 
inversion, left at room temperature for 2–3 min and then 
centrifuged at 2,000 × g for 5 min at 4 °C. The DNA pellet 100 
was recovered and maintained at −20 ◦C until analysis. To 
ensure the purity of the DNA, the absorbance of the sample 
was recorded on a UV-Vis spectrophotometer according to 




CRM was conducted with a Horiba Jobin-Yvon, LabRam 
HR800 instrument using a 785 nm laser as source. The 
laser power was approximately 70 mW at the sample. 110 
Spectra were taken in the range from 600 cm-1 to 1800 cm-
1 with a confocal hole diameter of 100μm. A 100 water 
immersion objective was used to focus the laser on the 
sample, immersed in 0.9% saline, yielding a spot size of 
~1m. Multiple spectra were recorded from the nuclear 115 
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portion of a total of 60 cells at each exposure level. 
Subsequently the spectra were filtered with a Savitsky-
Golay filter (order 5, 13 point window), and the quartz 
signal background was subtracted using algorithms 
developed in-house. Prior to analysis the spectra were also 5 
vector normalized. For the acquisition of the spectra from 
the extracted DNA, the DNA solution was drop cast onto 
quartz substrates. The Raman spectrum of pure cis-platin 




All spectral analysis was performed in the Matlab 7.2 (The 
Mathworks Inc.) environment employing the PLS Toolbox 
5.0.3 (Eigenvector Research, Wenatchee, WA) and 15 
algorithms developed in-house. Outlying spectra were 
removed using Grubb’s filtering18. All spectra, including 
calibration and substrate backgrounds, were vector 
normalized. The substrate spectra were subtracted from 
each spectrum and a fifth order polynomial was fitted to 20 
the spectra to remove any residual spectral baseline. 
Multivariate regression models were constructed using 
Partial Least Squares Regression (PLSR)19 and PLS Jack-
knifing was employed as a multivariate feature selection 
technique5, 20, 21. The PLSR algorithm seeks to develop a 25 
model that relates the spectral data (X-matrix) to a series of 
targets (Y-matrix, e.g. concentration of reaction product or 
analyte) according to the equation Y=XB+E, where B is a 
matrix of regression coefficients and E is the regression 
residual. The Y-matrix here consisted of values of the 30 
concentration of cisplatin to which the cell was exposed, or 
the measured level of cell viability from the MTT assay. 
The PLS Jack-knifing method developed by Westad and 
Martens21 was then used to determine the spectral features 
that were statistically significant at a particular level of 35 
confidence using t-testing of the regression coefficients, B. 
The Raman band assignments used in the interpretation of 
the spectral features were taken from the literature6, 22-25. 
 
Results and Discussion 40 
Cytotoxicity assay 
 
The MTT assay is a measure of the mitochondrial 
metabolic activity and in the current study is used initially 
as a standard against which to map the response as 45 
measured by CRM. Maximum cytotoxicity was observed 
after 96hrs exposure and thus this time period was 
employed for all measurements. The cytotoxicity induced 
in A549 cells due to the exposure to cisplatin for 96hrs, as 
determined by the MTT assay, is shown in Figure 1, 50 
where the level of viability in each sample was normalised 
to that in the control sample. Due to the action of the drug, 
the mitochondrial activity decreases monotonically which 
in turn leads to a decrease in cell viability. The Inhibitory 
Concentration (IC50) value was derived from the data by a 55 
fit of f(x) = min + (max-min)/(1+(x/IC50)^n) and found to 
be 1.2 ± 0.2μM, which is consistent with the literature. For 
A549 cells exposed to test drug concentration (TDC) for 
72 hrs, IC50  values of 3.59 μM and 2.2 μM are reported 
elsewhere with MTT and ATP assays respectively26. Also, 60 
Cordes et al. have determined an IC50 value of 2.0 μM for 
cisplatin (0.1-50 μM) exposed A549 cells using the colony 
formation assay27. 
  
Figure 1. A549 cell viability (measured by MTT absorption) at 96 hours 65 
after exposure to Cisplatin. Error bars denote the standard error on the 
mean at each concentration. 
 
Raman Spectrum of Cisplatin 
 70 
The Raman spectrum of pure cisplatin is shown in Figure 
2. The most prominent features lie in the region between 
100-550 cm-1 28, which does not fall within the 600-1800 
cm-1 spectral window of the current measurements and 
therefore they do not contribute to the cellular spectrum.  75 
 
 
Figure 2. Raman spectrum of cisplatin powder 
 
Nuclear spectral features 80 
 
Figure 3A shows the mean control spectra of the nucleus 
of A549 cells. The Raman bands which are important and 
in which changes due to the action of cisplatin may be 
expected are labelled. The Raman bands at 669 cm-1 and 85 
1375 cm-1 can be assigned to thymine and at 1336 cm-1 to 
guanine. Two bands at 807 cm-1 and 833 cm-1 are assigned, 
respectively, to the O-P-O stretching of the DNA-A and -B 
forms and the peak at 1095 cm-1 is assigned to the O-P-O 
stretching of the DNA backbone in general. Other 90 
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Figure 3. Mean spectrum of the nucleus of control sample (A) and the difference spectrum (B) between the mean of the control and the 
sample exposed to 3M cisplatin. The shaded area around each trace defines the standard error on the mean. 
 
Figure 4 Raman spectra of DNA extracted from A549 cells exposed to 3 µM cisplatin for 96 hrs; Mean control and exposed spectra (A) and
difference spectrum (B). The extent of each trace defines the mean spectrum plus the standard error on the mean (which are very small and thus
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Figure 5. Calibration (A) and test set performance (B) in prediction with PLSR of the cell viability using Raman spectra of the nucleus of A549 cells. Root 
mean squared errors of calibration (RMSEC) and prediction (RMSEP) are in units of cell viability, which themselves are normalized to the level in the 
control. 
prominent Raman bands derive from C-H deformation of 
lipids (1449 cm-1) and the amide-I band for proteins (1660 
cm-1). Lipid peaks (1480-1420 cm-1) in the nuclear spectra 
may originate from contributions of the surrounding 
cytoplasm8, 23.  5 
 
Figure 3B shows the mean difference spectrum of the 
nucleus of A549 cells exposed to 3 M cisplatin versus its 
control. The major changes observed are labelled. The 
bands for DNA bases including thymine (at 669cm-1 and 10 
1375 cm-1) and guanine (1336 cm-1) are significantly 
changed due to the binding of the cisplatin. As the cisplatin 
can form two types of intrastrand crosslinks, 1,2 GG and 
1,3 GTG, the Raman spectral changes (i.e. to the Raman 
bands of the Guanine(G) and thymine(T)) may indicate the 15 
presence of both types of crosslinkages due to the action of 
the cisplatin.15 The bands associated with the DNA-A and 
–B form are seen to change in intensity, the B-form band at 
833 cm-1 to a much greater degree. This could be indicative 
of the induction of conformational changes in the B-form 20 
of DNA due to the formation of intra-strand crosslinkages 
of the cisplatin with guanine and adenine and binding with 
thymine. This represents a Raman marker of the binding of 
cisplatin with the DNA bases. The changes observed in the 
bands for the O-P-O backbone of DNA, at 1095 cm-1, can 25 
be a marker for the changes in the electrostatic 
environment of the phosphate group29, 30. 
Changes in the bands at 1032 cm-1 (C-H stretching), 1128 
(C-N stretching) and 1660 cm-1 (amide-I), are related to 
protein structure. This may be due to the fact that after the 30 
conformational changes caused in the DNA by cisplatin 
binding, high mobility group proteins bind to the site 
where the cisplatin molecule has bound to the DNA and  
prevent repair by nuclease enzyme excision31.  
 35 
Spectral features of extracted nuclear DNA 
 
In order to further confirm the Raman markers for the 
known mechanism of action of the cisplatin, the spectra 
recorded of the DNA extracted from the control and 40 
exposed (3 µM for comparison to the spectroscopic 
analyses of the cells) A549 cells were analyzed. The mean 
control and the difference spectra of the extracted DNA are 
shown in Figure 4A and Figure 4B respectively. The 
DNA extracted from the unexposed control and the cis-45 
platin exposed samples were measured under identical 
conditions and thus it is concluded that the spectral 
differences are due to the cis-platin exposure alone, rather 
than the laser.  
Changes in the Raman bands of the DNA bases are 50 
observed, as expected, including guanine (1180 cm-1, 1335 
cm-1, 1450 cm-1, 1484 cm-1, 1578 cm-1), thymine (746 cm-1, 
1242, 1375) and adenine (1307 cm-1). Changes in the 
bands related to the DNA backbone, deoxyribose ring 
breathing (881 cm-1) and phosphodioxy stretching 55 
vibrations (1098 cm-1) are also observed, indicative of the 
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Figure 6. Feature selection in PLSR of Raman spectra of the A549 nucleus against (A) cisplatin concentrations and (B) against cellular 
viability. The shaded areas denote statistically significant features selected using PLS Jack-knifing with a t-test (p<0.001) of regression 
coefficients (shown in red with associated standard error).
 Prediction of exposure level and cellular  viability with PLSR 
 
CRM can clearly fingerprint the effects of the interaction 
of the chemotherapeutic agent with DNA, and identify that  
fingerprint within the cellular spectra of exposed cells. 5 
PLSR models of A549 nuclear spectra versus 
concentration and reference viability measurements from 
the MTT assay were constructed to determine the ability of  
the spectral data to predict the level of exposure to 
cisplatin and the associated level of physiological effect 10 
from Raman spectra. All spectra were compiled into a 
matrix, and were randomly sorted. A total of 60% of the 
spectra were used to train the PLSR regression model and 
of the total was retained as an independent test set to assess 
the performance of the model in predicting the level of 15 
exposure, and the cellular viability, with unseen data. 
Leave-one out cross validation with the calibration set was 
used to determine the optimal model complexity for use in 
testing32. This process was performed on fifty separate 
occasions, with randomization of the data matrix and 20 
splitting of the data on each occasion to prevent data bias19. 
An example of the results of prediction of levels of cellular 
viability is shown in Figure 5, where the values of the root 
mean square error of calibration (RMSEC) and the root 
mean square error of prediction (RMSEP) denote the 25 
prediction uncertainty. The mean values of the RMSEC 
and RMSEP for the PLSR for prediction of the level of 
exposure to cisplatin were found to be 1.67 M (0.45) and 
3.41 M (0.41) respectively, where the figures in brackets 
denote the standard deviations of these estimates. The 30 
associated values of RMSEC and RMSEP for PLSR 
against normalized cellular viability were 0.05 (0.008) and 
0.11 (0.011) respectively. The RMSEP for prediction of 
cisplatin concentration is therefore 6.8% over the full scale 
range (0 to 50 M), and 11% over the full scale range of 35 
viability (from 0 to 1). The proportionally higher observed 
errors of prediction of cell viability may be due to the 
development of cellular resistance to cisplatin over the 
exposure period in the low dose groups33, 34, which 
contributes to a non-linearity in the variation in viability 40 
with concentration that is difficult for the PLSR algorithm 
to model. 
 
Feature Selection by PLS Jack-knifing 
 45 
The spectral changes observed in Figure 2 are multivariate 
and may have complex exposure dependence. It has been 
demonstrated that they include the fingerprint of the 
interaction of the cisplatin with the nuclear DNA, but also 
evident are a multitude of other changes associated with 50 
exposure and changes in cellular physiology. In an effort to 
identify the most important spectral features, feature 
selection was performed using a Partial Least Squares – 
Jack knifing analysis described earlier. The regression co-
efficients were obtained by PLS-Jack knifing for separate 55 
regressions against cisplatin concentrations and against cell 
viability with the nuclear spectral data. To elucidate 
spectral changes that are most statistically significant with 
respect to regression against either endpoint, a t-test 
(p<0.001) was applied on the PLS-Jack knifing results, 60 
where the spectral features identified by this process are 
highlighted by vertical bands in Figure 6.  
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The PLS regression of the nuclear data against cisplatin 
concentration (Figure 5A), identifies many features but for 
the purpose of this discussion only the changes which are 
related to the known action of cisplatin are highlighted. 
Features identified include the thymine (737-742 cm-1, 5 
1589-1595 cm-1), guanine (1548-1553 cm-1) and adenine 
(1578 cm-1, 1604-1611 cm-1) bands. The regression co-
efficients of guanine and thymine are stronger than that of 
adenine indicating that cisplatin binds preferably with 
guanine as compared to adenine35. Another interesting 10 
observation is that the bands at (877-883 cm-1) and at (899-
900 cm-1) both assigned to deoxiribose ring breathing, are 
significantly changed, which lead to a change in the 
conformation of B-form DNA36-38. Changes in the Raman 
bands of the proteins are also highlighted, as indicated by 15 
the regression co-efficients which can be assigned to 
tryptophan ring breathing (761-765 cm-1), (889-891 cm-1), 
C-N stretching (1128-1132 cm-1), C-H deformation (1315-
1316 cm-1, 1351-1354 cm-1), amide-I (1668-1679 cm-1). 
These changes may indicate some structural changes in the 20 
nuclear proteins.  
 
The regression against cell viability (Figure 5B), shows the 
features which are changed significantly due to the change 
in cell physiology. These include the conformational 25 
changes of the DNA B-form (832-833 cm-1) and DNA A-
form (798-813 cm-1). These changes in the Raman bands of 
the DNA can be taken as markers for the conformational 
changes in the DNA caused by cisplatin binding to the 
guanine and thymine DNA bases15 and also confirm the 30 
observations from the mean difference spectra. Changes 
related to protein secondary and tertiary structures are 
indicated by the selection of amide-III random coil (1225-
1228 cm-1), amide-III β-sheet (1250-1259), amide-III alpha 
helix, tryptophan ring breathing (711-721 cm-1, 758-763 35 
cm-1, 767-772 cm-1) and phenyl ring stretching modes 
(1202-1210 cm-1) together with the C-C skeletal vibrations 
(935-937 cm-1, 1159-1163 cm-1), C-N stretching vibrations 
(1065-1068, 1073-1075) and C-H bending (1178-1182 cm-
1) (1185-1186 cm-1). These features suggest changes in the 40 
Raman bands of proteins and are indicative of structural 
alterations associated with protein activation and 
denaturation during cellular apoptosis and nucleic acid 
repair responses.  
 45 
Comparing the regression co-efficients obtained via 
spectral regression against cisplatin concentration (which 
highlight the primary biochemical effect of the action of 
the agent) with those obtained via regression against cell 
viability (which highlight biochemical markers of the 50 
change in the viability of the cell), very different spectral 
features are selected as being statistically significant and 
thus allow the differentiation of the chemotherapeutic 
response. The spectral features of thymine (737-742 cm-1, 
1589-1595 cm-1), guanine (1548-1553 cm-1) and adenine 55 
(1578 cm-1, 1604-1611 cm-1) feature prominently as a 
result of regression against the concentration of the 
chemotherapeutic agent and are attributable to direct 
binding of the cisplatin molecule with these DNA bases. In 
addition, changes related to proteins feature in the 60 
regression against the concentration of the 
chemotherapeutic agent are significantly different than 
those changes of protein associated bands which appear as 
a result of regression against the cellular viability. The 
changes in the features of the proteins due to the chemical 65 
effect are attributable to structural changes in nuclear 
histone proteins due to cisplatin interactions with the 
cellular DNA. These features are not selected as being 
statistically significant by the analysis for regression 
against the viability endpoint, suggesting that they are 70 
markers of the biochemical interaction between cisplatin 
and DNA. Contrastingly, the conformational changes to 
the DNA A-form (798-813 cm-1) and DNA B-form (832-
833 cm-1), among the changes associated with the protein 
features, especially the amide-III random coil (1225-1228 75 
cm-1), amide-III β-sheet (1250-1259), amide-III alpha 
helix, among others, are selected as being statistically 
significant in the regression against cellular viability 
suggesting that they are markers of this physiological 
endpoint in the chemotherapeutic response. Overall, Figure 80 
5 demonstrates that the Raman spectrum of the cell may be 
resolved into distinct groups of statistically significant 
spectral markers for distinct types of effect.  
 
“The study demonstrates the potential of commercially 85 
available benchtop CRM for the examination and 
prediction of chemotherapeutic responses. In general, for 
subcellular resolution, Raman spectroscopy is chosen over 
infrared spectroscopy due to the intrinsically higher spatial 
resolution. Furthermore, the relative insensitivity to water 90 
renders live cell imaging of real time exposures a 
possibility39. Nonlinear optical imaging techniques40 
promise even higher spatial resolution in the future, but at 
present such short pulse systems cannot be considered 
benchtop techniques.” 95 
 
 Cisplatin, a DNA major groove binder41, was chosen as a 
model as its mechanism of action is well characterised. To 
fully validate the technique, the study should be extended 
to other chemotherapeutic agents of known interaction 100 
mechanisms, such as tallimustine, a known DNA minor 
groove binder, and ethidium bromide, a known DNA 
intercalator. In this way the spectroscopic signatures of 
their interaction can be established and subsequently can 
act as a database against which novel chemotherapeutic 105 
agents can be evaluated. Ultimately, the techniques should 
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